Last reviewed · How we verify
Vitamin K Antagonist
At a glance
| Generic name | Vitamin K Antagonist |
|---|---|
| Also known as | Phenprocoumon, Warfarin, Acenocoumarol, As prescribed by treating physicians, warfarin, phenprocoumon, acecoumaril |
| Sponsor | RenJi Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- SIMPLAAFY Clinical Trial (NA)
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- SWITCH: Apixaban vs Vitamin K in HM3 (PHASE3)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin K Antagonist CI brief — competitive landscape report
- Vitamin K Antagonist updates RSS · CI watch RSS
- RenJi Hospital portfolio CI